Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that
may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted a …

Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …

Objective We undertook this phase III study to evaluate baricitinib, an orally administered
JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to …

Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor.
Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying …

Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral
inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite …

Objective. Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for
adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib’s …

Background The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was
evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. …

Objective To assess the frequency of cardiovascular and venous thromboembolic events in
clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more …

Background Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2,
approved for the treatment of patients with active rheumatoid arthritis. Because baricitinib, like …

Objective. To determine whether the correlation between the mean change in disease activity
and the mean change in synovial sublining (sl) CD68 expression could be demonstrated …